

NATIONAL RESEARCH COUNCIL,
Washington, D.C., January 24, 1969.

Dr. JOHN H. TALBOTT,
Editor, Journal of the American Medical Association, American Medical Association, Chicago, Illinois

DEAR DR. TALBOTT: Since our telephone conversation about the DES paper on fixed combinations of antimicrobial agents, Dr. Kunin has approved the attached draft, and I am forwarding it at once for your consideration.

As you know, we are hopeful that, if you see fit to publish the paper in JAMA, it can appear as nearly simultaneously as possible with FDA's announcement in the Federal Register. Thus, I would ask that you call me at your convenience when you have reviewed the report so that these arrangements can be discussed.

Please let me know if any problem of interpretation presents itself. Dr. Kunin has stated his willingness to help in this regard, and I will be glad to set up a conference call as indicated.

Sincerely,

DUKE C. TREXLER,
Executive Director.

cc: Dr. R. K. Cannan
Dr. C. L. Dunham
Dr. H. H. Hussey
Dr. C. M. Kunin
Enclosure.

NATIONAL RESEARCH COUNCIL,
Washington, D.C., January 29, 1969.

Dr. JOHN H. TALBOTT,
Editor, Journal of the American Medical Association, American Medical Association, Chicago, Illinois

DEAR DR. TALBOTT: As of this date, I have not been able to determine from FDA the date they will publish the Federal Register reports on the combinations referred to in our "white paper".

As you know, the "white paper" should be held in privileged category until we have this word from FDA, and I will write or call you about this as I am informed by FDA.

Sincerely,

DUKE C. TREXLER,
Executive Secretary.

cc: Dr. H. H. Hussey
Dr. C. M. Kunin

NATIONAL RESEARCH COUNCIL,
Washington, D.C., April 30, 1969.

Dr. JOHN H. TALBOTT,
Editor, Journal of the American Medical Association, Chicago, Illinois.

DEAR DR. TALBOTT. The high degree of interest in problems of therapeutic equivalence of drugs prompts us to transmit to you herewith the final version of the Drug Efficacy Study's "White Paper on Therapeutic Equivalence of Chemically Equivalent Drugs".

We feel free to authorize publication in the Journal of the American Medical Association of the text of the white paper together with editorial comment if you think such editorial comment to be desirable.

As you know, the white paper is prepared by a subcommittee of the Policy Advisory Committee of the Drug Efficacy Study. The subcommittee members are: Dr. W. B. Castle, Chairman; Dr. E. B. Astwood, Dr. Maxwell Finland, and Dr. Chester S. Keefer.

If any question presents itself with respect to the white paper on which you feel I might comment, please call on me.

Sincerely,

DUKE C. TREXLER,
Executive Director.

Enclosure.